I suppose we knew about pan-coronavirus conserved sites before, but it (imo) would have been too risky to try targeting those sites with the first mRNA vaccines - one experimental technology at a time.
They're lipid particles that are chemically very similar to your cell walls so they just fuse with the wall and then release their payload inside the cell.
That doesn't have anything to do with the target though. The stalk of the virus is difficult to target and not really possible with the existing way that influenza vaccines are manufactured with an inactivated virus process. So you wind up with the whole proteins and no good way to target segments. By using mRNA technology you can specify which protein you want to target or which segment of protein you want to target. It can also be useful to make edits to the protein sequence like the prefusion stabilization in the mRNA vaccines.
When you get the inactivated influenza vaccine you're still getting HA stalks attached to the HA protein and for whatever reason the immune system doesn't target the stalk sections well. So the idea is that you hit the immune system with a payload of only HA stalks and then hopefully the immune system pumps out antibodies specific for that which will then be resistant to genetic drift.
https://medicago.com/en/our-technologies/virus-like-particle...
https://en.wikipedia.org/wiki/Virus-like_particle
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905985/
(Disclosure: I was a participant in the phase 3 trial of Medicago's CoVLP/Covifenz vaccine)
https://www.statnews.com/2017/01/10/moderna-trouble-mrna/
"for its chemists, those [lipid] nanoparticles created a daunting challenge: Dose too little, and you don’t get enough enzyme to affect the disease; dose too much, and the drug is too toxic for patients."
"the Crigler-Najjar treatment has been indefinitely delayed, an Alexion spokeswoman told STAT. It never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Unable to press forward with that technology, Moderna has had to focus instead on developing a handful of vaccines"
Note the following paragraphs:
"mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects [snip] The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine"
In 2017 mRNA was considered "tricky" and with "nasty side effects". It was considered safe for vaccines by Moderna only because, they claimed, vaccines don't require repeat doses. This is surprising given that some countries now want to make mRNA vaccination a regular yearly event.
The reason they didn't focus on vaccines originally is related to that belief - vaccines are traditionally something you take once and are then protected for decades or for life. They are cheap and often bought by governments that demand bulk discounts, thus they are poor business compared to drugs that may require you to take them every week.